Bli medlem
Bli medlem

Du är här

2015-04-23

Active Biotech: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS

Phase II ARPEGGIO study design to be presented at the
67thAmerican Academy of Neurology (AAN) Annual Meeting
, April 18-25, 2015

Jerusalem, Israel&Lund, Sweden - April 23, 2015 -
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech
(NASDAQ STOCKHOLM: ACTI) today announced the first patient has been enrolled
in the studyA
R
andomizedP
lacebo-controlled TrialE
valuating Laquinimod in PPMS,G
augingG
radationsI
n MRI and ClinicalO
utcomes (ARPEGGIO), a Phase II study to evaluate laquinimod, an
investigational, oral, immune modulator, for the treatment of primary
progressive multiple sclerosis (PPMS). Currently there are no approved
treatments for PPMS, representing a condition with a high unmet need.

PPMS affects approximately 15 percent of all MS patients and is characterized
by the worsening of neurologic function without distinct relapses (also
called attacks or exacerbations). Unlike patients with relapsing-remitting MS
(RRMS), those with PPMS tend to have more lesions in the spinal cord than in
the brain and these brain lesions usually contain fewer inflammatory cells.
In addition, all studies evaluating RRMS treatments in patients with PPMS
have failed to prove effective for this condition.

"Laquinimod may represent an opportunity to help meet the challenge of PPMS,"
said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief
Scientific Officer at Teva. "The mechanisms of action and data from previous
studies in RRMS suggest the effect of laquinimod is focused on the
neurodegenerative aspects of the disease, which are pervasive in PPMS. We are
hopeful that the ARPEGGIO study will demonstrate the ability of laquinimod to
slow disability progression in PPMS and fulfill an unmet need for patients
with this lifelong and debilitating disease."

ARPEGGIO is a multinational, multicenter, randomized, double-blind,
parallel-group, placebo-controlled study of once-daily, oral laquinimod
(0.6mg or 1.5mg/day) in patients with PPMS. The study's primary endpoint is
percent brain volume change (PBVC) through MRI analysis. The trial will
enroll approximately 375 patients in the U.S., Canada, and Europe.

Additional details on the study design will be presented at the AAN Annual
Meeting in Washington, D.C. on Thursday, April 23, 2015 during Poster Session
7. For further details on the Phase II ARPEGGIO study, please
visitclinicaltrials.gov/show/NCT02284568.

About Laquinimod

Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator
with a novel mechanism of action being developed for the treatment of
relapsing-remitting MS (RRMS), progressive MS and Huntington's disease. The
global, Phase III, clinical development program evaluating laquinimod in MS
includes two completed pivotal studies, ALLEGRO and BRAVO (both 0.6mg/day). A
third Phase III trial, CONCERTO, is currently ongoing and evaluating two
doses of laquinimod (0.6mg and 1.2mg/day) in approximately 2,100 patients for
up to 24 months. The primary outcome measure is time to three-month
confirmed-disability progression as measured by the Expanded Disability
Status Scale (EDSS).

In the ALLEGRO and BRAVO trials, adverse reactions observed included headache,
abdominal pain, back and neck pain, appendicitis, and mild, asymptomatic
laboratory abnormalities, including liver enzyme elevations, hematological
changes and elevation of CRP or fibrinogen levels.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global
pharmaceutical company that delivers high-quality, patient-centric healthcare
solutions to millions of patients every day. Headquartered in Israel, Teva is
the world's largest generic medicines producer, leveraging its portfolio of
more than 1,000 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of the central
nervous system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of addressing
unmet patient needs by combining drug development capabilities with devices,
services and technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visitwww.tevapharm.com.

About Active Biotech

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod,
an orally administered small molecule with unique immunomodulatory
properties, is in pivotal phase III development for the treatment of
relapsing remitting multiple sclerosis. Also, laquinimod is in phase II
development for the treatment of primary progressive multiple sclerosis and
Huntington's disease.
The project portfolio includes a preclinical project, ISI, with the objective
to produce new, patentable chemical compounds for treatment of diseases
within the company's focus areas. Please visitwww.activebiotech.comfor more
information.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which are based on
management's current beliefs and expectations and involve a number of known
and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: our ability to develop and
commercialize additional pharmaceutical products; competition for our
innovative products, especially Copaxone®(including competition from
orally-administered alternatives, as well as from potential purported generic
equivalents)
and our ability to migrate users to our 40 mg/mL version; the possibility of
material fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters; our
ability to achieve expected results from the research and development efforts
invested in our pipeline of specialty and other products; our ability to
reduce operating expenses to the extent and during the timeframe intended by
our cost reduction program; our ability to identify and successfully bid for
suitable acquisition targets or licensing opportunities, or to consummate and
integrate acquisitions; the extent to which any manufacturing or quality
control problems damage our reputation for quality production and require
costly remediation; increased government scrutiny in both the U.S. and Europe
of our patent settlement agreements; our exposure to currency fluctuations
and restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the intellectual
property rights of our specialty medicines; the effects of reforms in
healthcare regulation and pharmaceutical pricing, reimbursement and coverage;
governmental investigations into sales and marketing practices, particularly
for our specialty pharmaceutical products; adverse effects of political or
economic instability, major hostilities or acts of terrorism on our
significant worldwide operations; interruptions in our supply chain or
problems with internal or third-party information technology systems that
adversely affect our complex manufacturing processes; significant disruptions
of our information technology systems or breaches of our data security;
competition for our generic products, both from other pharmaceutical
companies and as a result of increased governmental pricing pressures;
competition for our specialty pharmaceutical businesses from companies with
greater resources and capabilities; the impact of continuing consolidation of
our distributors and customers; decreased opportunities to obtain U.S. market
exclusivity for significant new generic products; potential liability in the
U.S., Europe and other markets for sales of generic products prior to a final
resolution of outstanding patent litigation; our potential exposure to
product liability claims that are not covered by insurance; any failure to
recruit or retain key personnel, or to attract additional executive and
managerial talent; any failures to comply with complex Medicare and Medicaid
reporting and payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the effects of
increased leverage and our resulting reliance on access to the capital
markets; potentially significant increases in tax liabilities; the effect on
our overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our business;
variations in patent laws that may adversely affect our ability to
manufacture our products in the most efficient manner; environmental risks;
and other factors that are discussed in our Annual Report on Form 20-F for
the year ended December 31, 2014 and in our other filings with the U.S.
Securities and Exchange Commission. Forward-looking statements speak only as
of the date on which they are made and we assume no obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or otherwise.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish
Securities Market Act

This press release contains certain forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties and
other important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from
any future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or
publicly release any revisions to forward-looking statements to reflect
events, circumstances or changes in expectations after the date of this press
release.

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This
information was provided to the media for publication at 8:00 pm CET on April
23, 2015.

# # #

Teva and Active Biotech Announce First Patient Enrolled in Phase II
http://hugin.info/1002/R/1913972/683780.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.